A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Trial Profile

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs AU 011 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Aura Biosciences
  • Most Recent Events

    • 30 Oct 2018 According to an Aura Biosciences media release,company Presents Updated Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting
    • 30 Oct 2018 Results published in the Aura Biosciences Media Release
    • 23 Jul 2018 According to an Aura Biosciences media release, Aura plans to complete the enrollment of this trial in October.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top